Baker Brothers Affiliate Files Intent to Sell $220K in Protara Therapeutics Shares Amid Coordinated Disposition
Summary
667, L.P., an affiliate of Baker Brothers Life Sciences, has filed a Form 144 indicating its intent to sell 35,173 shares of Protara Therapeutics common stock, valued at approximately $220,151. This is part of a larger, coordinated disposition by the institutional investor group.
Key Events
-
Intent to Sell Shares
667, L.P., an affiliate of Baker Brothers Life Sciences, intends to sell 35,173 shares of Protara Therapeutics common stock.
-
Significant Transaction Value
The proposed sale is valued at approximately $220,151.
-
Part of Coordinated Disposition
This sale is explicitly linked to a larger, coordinated disposition by the Baker Brothers group, totaling 459,298 shares across related filings.
-
Institutional Investor Selling
The filer is a "Former Affiliate" of Baker Brothers Life Sciences, indicating a reduction in their investment.
Analysis
This Form 144 filing from 667, L.P., an affiliate of Baker Brothers Life Sciences, signals a continued reduction in their stake in Protara Therapeutics. While the proposed sale of 35,173 shares (valued at approximately $220,151) is modest on its own, the filing explicitly states it's part of a larger, coordinated disposition by the institutional group totaling 459,298 shares across related filings. This ongoing selling pressure from a significant former affiliate could create an overhang on the stock, especially following recent positive clinical trial results which might have provided a liquidity window for the investor. Investors should monitor further filings from this group for signs of a complete exit or continued selling pressure.
At the time of this filing, TARA was trading at $6.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.1M. The 52-week trading range was $2.77 to $7.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.